McNamara fallacy

The McNamara fallacy (also known as quantitative fallacy[1]), named for Robert McNamara, the United States Secretary of Defense from 1961 to 1968, involves making a decision based solely on quantitative observations and ignoring all others. The reason given is often that these other observations cannot be proven. (See the example below.)

It refers to McNamara's belief as to what led the United States to defeat in the Vietnam War—specifically, his quantification of success in the war (e.g. in terms of enemy body count), ignoring other variables.

The first step is to measure whatever can be easily measured. This is OK as far as it goes. The second step is to disregard that which can't be easily measured or to give it an arbitrary quantitative value. This is artificial and misleading. The third step is to presume that what can't be measured easily really isn't important. This is blindness. The fourth step is to say that what can't be easily measured really doesn't exist. This is suicide.
— Daniel Yankelovich "Corporate Priorities: A continuing study of the new demands on business." (1972)

Examples

In modern clinical trials

There has been increasing discussion of the McNamara fallacy in medical literature.[2][3] In particular, the McNamara fallacy is invoked to describe the futility of using progression-free survival (PFS) as a primary endpoint in clinical trials for agents treating metastatic solid tumors simply because PFS is an endpoint which is merely measurable, while failing to capture outcomes which are more meaningful such as overall quality of life or overall survival.

See also

References

  1. ↑ Fischer, D. H. (June 1970). Historians' fallacies: toward a logic of historical thought. Harper torchbooks (first ed.). New York: HarperCollins. p. 90. ISBN 978-0-06-131545-9. OCLC 185446787.
  2. ↑ Basler, Michael H. (2009). "Utility of the McNamara fallacy". BMJ. 339: b3141. doi:10.1136/bmj.b3141.
  3. ↑ Booth, Christopher M.; Eisenhauer, Elizabeth A. (2012). "Progression-Free Survival: Meaningful or Simply Measurable?". Journal of Clinical Oncology. 30 (10): 1030–1033. doi:10.1200/JCO.2011.38.7571.
This article is issued from Wikipedia - version of the 10/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.